NCT04236219 - ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

November 6, 2020

Study Completion Date

November 6, 2020

Conditions

Hyperuricemia

Interventions

DRUG

ALLN-346

ALLN-346 is novel urate oxidase provided as capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.

DRUG

Placebo

Matching placebo capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.

Trial Locations (1)

45227

Medpace Clinical Pharmacology, Cincinnati